logo

Health News

Share
sugarydrinks-july11.jpgSugary drinks are associated with a number of health problems such as obesity, high blood pressure, type 2 diabetes to name a few, and yet they are a beverage of choice for many. The findings from the French NutriNet-Santé cohort study suggest a possible link between sugary drinks and cancer.
Read More

curaleaf-july22.jpgCannabis company Curaleaf Holdings Inc. has agreed to acquire privately-held GR Companies, Inc. or Grassroots, for about $875 million in cash and stock. The acquisition will make Wakefield, Massachusetts-based Curaleaf the world's largest cannabis company by revenue and the largest in the U.S. by other key operating metrics. It will also expand Curaleaf's presence to 19 states.
Read More
hiv-july03.jpg

First-of-kind Study Eliminates HIV From Infected Animals



Finding a cure for AIDS has been elusive. That said, there is always some hope as a new study aimed at finding a magic bullet to cure HIV has shown some promising results.
Read More
pigs-april18.jpg

No Piggy Tale: Some Brain Functions Restored Even Hours After Death



The conventional wisdom is that if the brain cells of humans and other mammals are deprived of oxygen for 4-5 min, they begin to die, and that the loss of brain functions after death is irreversible. But the findings of a study conducted by Yale University researchers challenge these long-held assumptions.
Read More
mekinist-april30.jpgScientists at the Université de Montréal and CHU Sainte-Justine Research Cente are said to have made a discovery, which could be a promising treatment for patients with Noonan Syndrome.
Read More
Follow RTT


FDA Calendar
Event DateSymbolDrug NameEvent Name
10/19/19CLSDXIPERE (NDA)FDA decision on XIPERE for Suprachoroidal Injection for macular edema associated with uveitis
10/14/19FLXNZILRETTA (sNDA)FDA decision on the repeat administration of ZILRETTA for patients with osteoarthritis knee pain
09/28/19AMRN Vascepa (sNDA) FDA decision on Vascepa to reduce residual cardiovascular risk in patients with statin-managed LDL-C cholesterol
09/27/19ITCILumateperone (NDA)FDA decision on Lumateperone for the treatment of schizophrenia
09/15/19AVDLAV001 (NDA)FDA decision on AV001 for Hospital product
09/13/19AIMTAR101 (BLA)FDA panel to review AR101 for Peanut Allergy
View All